Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for serious diseases. The company's lead programs include EB-101, a gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, and ABO-102, a gene therapy for Sanfilippo syndrome type A. Abeona is also developing ABO-101, a gene therapy for Sanfilippo syndrome type B, and ABO-201, a gene therapy for CLN3 disease. The company was founded in 1974 and is headquartered in New York, NY.